Pfenex, BARDA Extends Anthrax Vaccine Pact

Article

Pfenex modifies its contract with US government for Anthrax vaccine.

Pfenex, a biotechnology company offering recombinant protein expression, and the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), have modified its prime contract and exercised an option associated with their existing contractual relationship that began in July 2010. This modified agreement extends the prime contract and increases the funding to support the development of a recombinant protective antigen (rPA)-based anthrax vaccine based on rPA produced in the company’s platform technology, Pfēnex Expression Technology.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised.

During the contract’s base period, Pfenex demonstrated that a strongly immunogenic, stable, and protective form of rPA could be expressed and recovered from the fermentation of a strain of P. fluorescens engineered to produce rPA. The exercise of this option allows for the completion of preclinical studies, implementation of analytical methods, and cGMP manufacturing.

Source: Pfenex

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.